je.st
news
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
2015-04-08 03:15:03| Trucking - Topix.net
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers For a near-term outlay of nearly $100m, Bristol-Myers gets the heart failure candidate AAV-S100A1 and three other targets. Along with Bluebird Bio , Celladon and Voyager Therapeutics, UniQure shows that gene therapy has begun a modest but noteworthy renaissance.
Tags: advanced
interest
deal
confirms
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||